Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 10/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | IL6ST | P40189 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940861 | 1.00 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL3940865 | 1.00 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL4015232 | 1.00 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14645217 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14718277 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14645216 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14645224 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14645206 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL14645207 | 0.85 | NAAA (0.42) | NAAACSNK2BCSNK2A1FAAHIDH1 | |
| SCHEMBL5316186 | 0.84 | RIPK1 (0.43) | NAAACSNK2BCSNK2A1FAAHIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | NAAA 3276/4885CSNK2B 2859/4885CSNK2A1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.